var data={"title":"Montelukast: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Montelukast: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6601?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=montelukast-patient-drug-information\" class=\"drug drug_patient\">see &quot;Montelukast: Patient drug information&quot;</a> and <a href=\"topic.htm?path=montelukast-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Montelukast: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197951\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Singulair</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197952\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACH-Montelukast;</li>\n      <li>Apo-Montelukast;</li>\n      <li>Auro-Montelukast;</li>\n      <li>Auro-Montelukast Chewable Tablets;</li>\n      <li>Dom-Montelukast;</li>\n      <li>Dom-Montelukast FC;</li>\n      <li>Jamp-Montelukast;</li>\n      <li>Mar-Montelukast;</li>\n      <li>Mint-Montelukast;</li>\n      <li>Montelukast Sodium Tablets;</li>\n      <li>Mylan-Montelukast;</li>\n      <li>PMS-Montelukast;</li>\n      <li>PMS-Montelukast FC;</li>\n      <li>RAN-Montelukast;</li>\n      <li>Riva-Montelukast FC;</li>\n      <li>Sandoz-Montelukast;</li>\n      <li>Sandoz-Montelukast Granules;</li>\n      <li>Singulair;</li>\n      <li>Teva-Montelukast</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197987\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Leukotriene Receptor Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197955\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Patients with <b>both</b> asthma and allergic rhinitis should take only one dose in the evening.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Allergic rhinitis (perennial or seasonal):</b> Oral: 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Asthma:</b> Oral: 10 mg once daily (in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Bronchoconstriction, exercise-induced (prevention):</b> Oral: 10 mg at least 2 hours prior to exercise. <b>Note:</b> Additional  doses should not be administered within 24 hours. Daily administration to prevent exercise-induced bronchoconstriction has not been evaluated. Patients receiving montelukast for another indication should not take an additional dose to prevent exercise-induced bronchoconstriction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic urticaria (off-label use):</b> Oral: 10 mg once daily (DiLorenzo 2004; Nettis 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Urticaria (nonsteroidal anti-inflammatory drug&ndash;induced) (off-label use):</b> Oral: 10 mg once daily (Pacor 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197972\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=montelukast-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Montelukast: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Patients with <b>both</b> asthma and allergic rhinitis should take only one dose in the evening.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Asthma:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children &ge;1 to &lt;2 years:</i> 4 mg (oral granules) once daily (in the evening) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children &ge;2 to &lt;6 years:</i> 4 mg (chewable tablet or oral granules) once daily (in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children &ge;6 years and Adolescents &lt;15 years:</i> 5 mg (chewable tablet) once daily (in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Adolescents &ge;15 years:</i> 10 mg once daily (in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Bronchoconstriction, exercise-induced (prevention): Note:</b> Additional doses should not be administered within 24 hours. Daily administration to prevent exercise-induced bronchoconstriction has not been evaluated. Patients receiving montelukast for another indication should not take an additional dose to prevent exercise-induced bronchoconstriction. Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children &ge;6 years and Adolescents &lt;15 years:</i> 5 mg (chewable tablet) at least 2 hours prior to exercise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Adolescents &ge;15 years:</i> 10 mg once daily at least 2 hours prior to exercise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Perennial allergic rhinitis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children 6 months to &lt;2 years:</i> 4 mg (oral granules) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children &ge;2 to &lt;6 years:</i> 4 mg (chewable tablet or oral granules) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children &ge;6 years and Adolescents &lt;15 years:</i> 5 mg (chewable tablet) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Adolescents &ge;15 years:</i> 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Seasonal allergic rhinitis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children &ge;2 to &lt;6 years:</i> 4 mg (chewable tablet or oral granules) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children &ge;6 years and Adolescents &lt;15 years:</i> 5 mg (chewable tablet) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Adolescents &ge;15 years:</i> 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Urticaria (nonsteroidal anti-inflammatory drug-induced) (off-label use):</b> Oral: Adolescents &ge;15 years: 10 mg once daily (Pacor 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197956\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197957\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197958\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild-to-moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling; has not been studied. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197926\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Singulair: 4 mg (30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg (1 ea, 30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Singulair: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Singulair: 4 mg, 5 mg [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg, 5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197912\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197928\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">When treating asthma, administer dose in the evening. Patients with allergic rhinitis may individualize administration time (morning or evening). Patients with <b>both</b> asthma and allergic rhinitis should take a single dose in the evening. May administer without regard to food or meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Granules: May be administered directly in the mouth, dissolved in 5 mL of baby formula or breast milk, or mixed with a spoonful of applesauce, carrots, rice, or ice cream; do not add to any other liquids or foods. Administer within 15 minutes of opening packet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197927\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prophylaxis and chronic treatment of asthma; relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis; prevention of exercise-induced bronchoconstriction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> American Academy of Otolaryngology, Head and Neck Surgery (AAO-HNS) and American Academy of Allergy, Asthma, and Immunology (AAAAI) and American College of Allergy, Asthma, and Immunology (ACAAI) guidelines recommend <i>against</i> montelukast use as first-line therapy for allergic rhinitis (except in patients with concurrent asthma) (Dykewicz 2017; Seidman 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469181\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chronic urticaria; Urticaria (nonsteroidal anti-inflammatory drug&ndash;induced)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197994\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Singulair may be confused with Oralair, SINEquan</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197919\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (children and adolescents: &ge;2%), dizziness (adolescents and adults: 2%), fatigue (adolescents and adults: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Atopic dermatitis (children: &ge;2%), dermatitis (children: &ge;2%), eczema (children: &ge;2%), skin infection (children: &ge;2%), urticaria (children: &ge;2%), skin rash (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (children: &ge;2%), diarrhea (children and adolescents: &ge;2%), nausea (children and adolescents: &ge;2%), tooth infection (children: &ge;2%), dyspepsia (2%), gastroenteritis (2%), toothache (adolescents and adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Pyuria (adolescents and adults: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (adolescents and adults: 2%), increased serum ALT (adolescents and adults: &ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (children and adolescents: &ge;2%), varicella (children: &ge;2%), viral infection (children and adolescents: &ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (adolescents and adults: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (children: &ge;2%), myopia (children: &ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (children: &ge;2%), otitis (children and adolescents: &ge;2%), otitis media (children and adolescents: &ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (3%), acute bronchitis (children: &ge;2%), laryngitis (children and adolescents: &ge;2%), pharyngitis (children: &ge;2%), pneumonia (children: &ge;2%), rhinitis (infective; children: &ge;2%), rhinorrhea (children: &ge;2%), nasal congestion (adolescents and adults: 2%), epistaxis (adolescents and adults: &ge;1%), sinus headache (adolescents and adults: &ge;1%), sinusitis (&ge;1%), upper respiratory tract infection (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (2%), trauma (adolescents and adults: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Abnormal dreams, aggressive behavior, agitation, anaphylaxis, angioedema, anxiety, arthralgia, behavioral changes, bruise, eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss), depression, diarrhea, disorientation, drowsiness, edema, eosinophilia (systemic), eosinophilic pneumonitis, epistaxis, erythema multiforme, erythema nodosum, hallucination, hemorrhagic diathesis, hepatic eosinophilic infiltration, hepatitis (mixed pattern, hepatocellular, and cholestatic), hostility, hypersensitivity reaction, hypoesthesia, insomnia, irritability, lack of concentration, memory impairment, mood changes, muscle cramps, myalgia, nausea, palpitations, pancreatitis, paresthesia, pruritus, restlessness, seizure, somnambulism, Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, thrombocytopenia, tics, toxic epidermal necrolysis, tremor, urinary incontinence, urticaria, vasculitis, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197931\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to montelukast or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197916\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Eosinophilia and vasculitis: In rare cases, patients may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss), a condition which is often treated with systemic corticosteroid therapy. Healthcare providers should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between montelukast and these underlying conditions has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric events: Postmarketing reports of behavioral changes (eg, abnormal dreams, agitation, aggression, anxiety, attention deficit, depression, disorientation, hallucinations, hostility, insomnia, irritability, memory disturbances, restlessness, sleep disturbance, suicide ideation/behavior, and tremor) have been noted in pediatric, adolescent, and adult patients. In a retrospective analysis performed by Merck, serious behavior-related events were rare (Philip, 2009a); assess patients for behavioral changes. Patients should be instructed to notify the prescriber if behavioral changes occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute asthma/bronchospasm: Not FDA approved for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. Some studies, however, support its use as adjunctive therapy (Cylly, 2003; Ferreira, 2001; Harmancik, 2006). Appropriate rescue medication should be available. Montelukast treatment should continue during acute asthma exacerbation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aspirin-sensitive asthmatics: Montelukast will not interrupt bronchoconstrictor response to aspirin or other NSAIDs. Patients with known aspirin sensitivity should continue to avoid these agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Corticosteroids: When inhaled or systemic corticosteroid reduction is considered in patients initiating or receiving montelukast, appropriate clinical monitoring and a gradual dose reduction of the steroid are recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chewable tablet: Contains phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197980\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C8 (minor), CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197921\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9539&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Gemfibrozil: May increase the serum concentration of Montelukast.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of Montelukast.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197923\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197934\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Birth defects have been reported (rarely) following maternal use; however, a causal relationship with montelukast has not been established. Based on available data, an increased risk of teratogenic effects has not been observed with montelukast use in pregnancy (BTS 2016; GINA 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. When clinically indicated, treatment with montelukast should not be withheld during pregnancy (BTS 2016; GINA 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20471548\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Montelukast is present in breast milk (Datta 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of montelukast is 0.68% when calculated using an average breast milk concentration compared to a weight-adjusted maternal dose of 10 mg/day (Datta 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of montelukast was calculated using an average milk concentration of 5.3 ng/mL (average range: 2.87 to 9.12 ng/mL), providing an estimated daily infant dose via breast milk of 0.798 mcg/kg/day. The average milk concentration was obtained following chronic maternal administration of oral montelukast 10 mg daily in 7 patients at 1.4 to 8.2 months' postpartum. The weight-adjusted maternal dose was calculated using the mean weight (85.7 kg) of the patients included in the study. No adverse events were reported in the breastfeeding persons or their infants (Datta 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer recommends that caution be exercised when administering montelukast to breastfeeding patients. Patients with asthma should be encouraged to breastfeed their infants (GINA 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197936\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5952224\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Mood or behavior changes, including suicidal thinking/behavior</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197915\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selective leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Cysteinyl leukotrienes are also released from the nasal mucosa following allergen exposure leading to symptoms associated with allergic rhinitis (Jarvis, 2000). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197930\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: &gt;24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 8 to 11 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: &gt;99% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via CYP3A4, 2C8, and 2C9</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Tablet: 10 mg, Mean: 64%; Chewable tablet: 5 mg: 73% (63% when administered with a standard meal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 2.7 to 5.5 hours; Mild-to-moderate hepatic impairment: 7.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Tablet: 10 mg: 3 to 4 hours (fasting); Chewable tablet: 4 mg (children 2 to 5 years): 2 hours (fasting); Chewable tablet 5 mg: 2 to 2.5 hours (fasting); Granules: 2.3 &plusmn; 1 hours (fasting) and 6.4 &plusmn; 2.9 hours (with high-fat meal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (86%); urine (&lt;0.2%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197933\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Montelukast Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $169.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $169.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Singulair Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $273.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $273.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Montelukast Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $179.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Singulair Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $273.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Montelukast Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $169.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Singulair Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $273.96</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197937\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actamone (SG);</li>\n      <li>Actamone FC (SG);</li>\n      <li>Aeron (LK);</li>\n      <li>Airfast (QA);</li>\n      <li>Airlukast (PE);</li>\n      <li>Altra (MY);</li>\n      <li>Amikast (BD);</li>\n      <li>Anxokast (TW);</li>\n      <li>Asmaact (HK);</li>\n      <li>Asmax (HK);</li>\n      <li>Astair (TH);</li>\n      <li>Asthator (RO, TZ);</li>\n      <li>Asthmatin (HK);</li>\n      <li>Blow (CO);</li>\n      <li>Breathezy (TZ);</li>\n      <li>Brecare (PH);</li>\n      <li>Cubraxis (MX);</li>\n      <li>Edron (BD);</li>\n      <li>Everest (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Glemont (MY);</li>\n      <li>Glemont-CT (PH);</li>\n      <li>Glemont-IR (PH);</li>\n      <li>Inmunobron (PY);</li>\n      <li>Kastair (PH);</li>\n      <li>Kastair EZ (PH);</li>\n      <li>Kipel (TZ);</li>\n      <li>Kipres (JP);</li>\n      <li>Leukast (PH, QA);</li>\n      <li>Lukair (KR);</li>\n      <li>Lukakline (MY, SG);</li>\n      <li>Lukast (CO, JO);</li>\n      <li>Lumona (BD);</li>\n      <li>Lungair (LK);</li>\n      <li>Mediruka (KR);</li>\n      <li>Milukant (UA);</li>\n      <li>Miralust (MT);</li>\n      <li>Mokast (TW);</li>\n      <li>Monarin (ID);</li>\n      <li>Monas (BD);</li>\n      <li>Monest (HR);</li>\n      <li>Monkalus (KR);</li>\n      <li>Monolair (KR);</li>\n      <li>Montair (IN, PH);</li>\n      <li>Montecad (PH);</li>\n      <li>Montegol (VN);</li>\n      <li>Montek-10 (TH);</li>\n      <li>Monteka (TW);</li>\n      <li>Montekast (PH);</li>\n      <li>Montel (QA);</li>\n      <li>Montelair (HK, IE, LK, MT, MY, SG);</li>\n      <li>Montelu V (KR);</li>\n      <li>Monteluk (LK);</li>\n      <li>Montelukan (KR);</li>\n      <li>Montelukan QDT (KR);</li>\n      <li>Montemax (PH);</li>\n      <li>Montepect (KR);</li>\n      <li>Montexin (TW);</li>\n      <li>Montiget (PH, VN);</li>\n      <li>Montulair (TH);</li>\n      <li>Oxair (MY);</li>\n      <li>Regulair (SG);</li>\n      <li>Reversair (BD);</li>\n      <li>Romilast (TZ);</li>\n      <li>Sansibast (MX);</li>\n      <li>Singkalus Chewable (KR);</li>\n      <li>Singulair (AE, AR, AT, AU, BB, BE, BG, BH, BM, BO, BR, BS, BZ, CH, CL, CN, CR, CY, CZ, DE, DK, DO, EE, EG, ES, FI, FR, GB, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JM, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, QA, RO, RU, SA, SE, SG, SI, SK, SR, SV, TH, TR, TT, TW, UY, VE, VN);</li>\n      <li>Singular Chew (KR);</li>\n      <li>Sinkast (JO, TW);</li>\n      <li>Smart-Air (VN);</li>\n      <li>Synhlon (UA);</li>\n      <li>Synhulyar (UA);</li>\n      <li>Tekast (PH);</li>\n      <li>Telkast (TZ);</li>\n      <li>Unicast (JO);</li>\n      <li>Valtrover (CR, DO, HN, NI, PA, SV);</li>\n      <li>Valttrover (GT);</li>\n      <li>Vizendo (RO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Attwood SE, Lewis CJ, Bronder CS, Morris CD, Armstrong GR, Whittam J. Eosinophilic oesophagitis: a novel treatment using montelukast. <i>Gut</i>. 2003;52(2):181-185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/12524397/pubmed\" target=\"_blank\" id=\"12524397\">12524397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bakhireva LN, Jones KL, Schatz M, et al, &ldquo;Organization of Teratology Information Specialists Collaborative Research Group. Safety of Leukotriene Receptor Antagonists in Pregnancy,&rdquo; <i>J Allergy Clin Immunol</i>, 2007, 119(3):618-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/16708374/pubmed\" target=\"_blank\" id=\"16708374\">16708374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    British Thoracic Society (BTS) Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Revised 2016. Availabe at http://www.sign.ac.uk/sign-153-british-guideline-on-the-management-of-asthma.html.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Camargo CA Jr, Smithline HA, Malice MP, et al, &ldquo;A Randomized Controlled Trial of Intravenous Montelukast in Acute Asthma,&rdquo; <i>Am J Respir Crit Care Med</i>, 2003, 167(4):528-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/12456380/pubmed\" target=\"_blank\" id=\"12456380\">12456380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cylly A, Kara A, Ozdemir T, et al, &ldquo;Effects of Oral Montelukast on Airway Function in Acute Asthma,&rdquo; <i>Respir Med</i>, 2003, 97(5):533-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/12735671/pubmed\" target=\"_blank\" id=\"12735671\">12735671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Datta P, Rewers-Felkins K, Baker T, Hale TW. Transfer of montelukast into human milk during lactation. <i>Breastfeed Med</i>. 2017;12:54-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/28002678/pubmed\" target=\"_blank\" id=\"28002678\">28002678</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA; American College of Gastroenterology. ACG clinical guideline: evidence based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). <i>Am J Gastroenterol</i>. 2013;108(5):679-692.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/23567357/pubmed\" target=\"_blank\" id=\"23567357\">23567357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. <i>J Allergy Clin Immunol</i>. 2004;114(3):619-625.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dykewicz MS, Wallace DV, Baroody F, Bernstein J, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. <i>Ann Allergy Asthma Immunol</i>. 2017;119(6):489-511.e41. doi: 10.1016/j.anai.2017.08.012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/29103802/pubmed\" target=\"_blank\" id=\"29103802\">29103802</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferreira MB, Santos AS, Pregal AL, et al, &ldquo;Leukotriene Receptor Antagonists (Montelukast) in the Treatment of Asthma Crisis: Preliminary Results of a Double-Blind Placebo Controlled Randomized Study,&rdquo; <i>Allerg Immunol (Paris)</i>, 2001, 33(8):315-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. Available at http://www.ginasthma.org. Updated 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harmanci K, Bakirtas A, Turktas I, et al, &ldquo;Oral Montelukast Treatment of Preschool-Aged Children With Acute Asthma,&rdquo; <i>Ann Allergy Asthma Immunol</i>, 2006, 96(5):731-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/16729788/pubmed\" target=\"_blank\" id=\"16729788\">16729788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000; 343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. <i>J Allergy Clin Immunol</i>. 2011;128(1):3-20.e6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/21477849/pubmed\" target=\"_blank\" id=\"21477849\">21477849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucendo AJ, de Rezende LC, Jim&eacute;nez-Contreras S, et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. <i>Dig Dis Sci</i>. 2011;56(12)3551-3558.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/21674173/pubmed\" target=\"_blank\" id=\"21674173\">21674173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jarvis B and Markham A, &quot;Montelukast: A Review of Its Therapeutic Potential in Persistent Asthma,&quot; <i>Drugs</i>, 2000, 59(4):891-928.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/10804041/pubmed\" target=\"_blank\" id=\"10804041\">10804041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lougheed MD, Lemi&egrave;re C, Dell SD, et al, &ldquo;Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,&rdquo; <i>Can Respir J</i>, 2010, 17(1):15-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/20186367/pubmed\" target=\"_blank\" id=\"20186367\">20186367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelsen LM, Shields KE, Cunningham ML, et al, &quot;Congenital Malformations Among Infants Born to Women Receiving Montelukast, Inhaled Corticosteroids, and Other Asthma Medications,&quot; <i>J Allergy Clin Immunol</i>, 2012, 129(1):251-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/22000568/pubmed\" target=\"_blank\" id=\"22000568\">22000568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria:a randomized, double-blind, placebo-controlled study. <i>Clin Exp Allergy</i>. 2004;34(9):1401-1407.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11678862\"></a>Pacor ML, Di Lorenzo G, Corrocher R, et al, &quot;Efficacy of Leukotriene Receptor Antagonist in Chronic Urticaria. A Double-Blind, Placebo-Controlled Comparison of Treatment With Montelukast and Cetirizine in Patients With Chronic Urticaria With Intolerance to Food Additive and/or Acetylsalicylic Acid,&quot; <i>Clin Exp Allergy</i>, 2001, 31(10):1607-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/11678862/pubmed\" target=\"_blank\" id=\"11678862\">11678862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philip G, Hustad CM, Malice MP, et al, &ldquo;Analysis of Behavior-Related Adverse Experiences in Clinical Trials of Montelukast,&rdquo; <i>J Allergy Clin Immunol</i>, 2009a, 124(4):699-706.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/19815116/pubmed\" target=\"_blank\" id=\"19815116\">19815116</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philip G, Hustad C, Noonan G, et al, &ldquo;Reports of Suicidality In Clinical Trials Of Montelukast,&rdquo; <i>J Allergy Clin Immunol</i>, 2009b, 124(4):691-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/19815114/pubmed\" target=\"_blank\" id=\"19815114\">19815114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sarkar M, Koren G, Kalra S, et al, &ldquo;Montelukast Use During Pregnancy: A Multicentre, Prospective, Comparative Study of Infant Outcomes,&rdquo; <i>Eur J Clin Pharmacol</i> 2009, 65(12);1259-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/19707749/pubmed\" target=\"_blank\" id=\"19707749\">19707749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seidman MD, Gurgel RK, Lin SY, et al; Guideline Otolaryngology Development Group. AAO-HNSF. Clinical practice guideline: Allergic rhinitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(1 Suppl):S1-S43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/montelukast-drug-information/abstract-text/25644617/pubmed\" target=\"_blank\" id=\"25644617\">25644617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singulair (montelukast) [prescribing information]. Whitehouse Station, NJ: Merck and Co; December 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9539 Version 237.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F197951\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F197952\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F197987\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F197955\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F197972\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F197956\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F197957\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F197958\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F197926\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F197912\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F197928\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F197927\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469181\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F197994\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F197919\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F197931\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F197916\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F197980\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F197921\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F197923\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F197934\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20471548\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F197936\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5952224\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F197915\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F197930\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F197933\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F197937\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9539|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=montelukast-patient-drug-information\" class=\"drug drug_patient\">Montelukast: Patient drug information</a></li><li><a href=\"topic.htm?path=montelukast-pediatric-drug-information\" class=\"drug drug_pediatric\">Montelukast: Pediatric drug information</a></li></ul></div></div>","javascript":null}